Back to search results

Observational Study on Atrial Fibrillation (AFib) Biomarkers

This study aims to better understand Atrial Fibrillation (AFib), a common irregular heart rhythm. Researchers want to find new ways to identify people most at risk for developing AFib, those whose AFib might worsen, or those who may not respond well to current treatments. You might be eligible if you are at least 18 years old, speak English, and have a history of AFib or are undergoing treatment for it. The study will involve monitoring your heart rhythm with mobile devices, collecting blood and saliva samples, and performing heart imaging (Echo). The main goals are to see how AFib develops and progresses over 10 years.

Study design
This is an observational study planning to enroll 3000 participants. It is designed to follow participants over time without assigning specific treatments.
What's involved
You will receive mobile devices for remote heart monitoring and have serial blood draws, saliva collections, and heart imaging (Echo) at baseline and yearly for three years. You will also complete electronic surveys every 3-6 months.
Compensation
Not stated in the trial record.
Follow-up
The study will follow participants for 10 years to observe the development or progression of AFib.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04404465

Health eHeart BEAT-AFib - Health eHeart Biomarkers of Early Atrial Transformation in Atrial Fibrillation

Enrolling by Invitation
Not specifiedAges 18+Observational
University of California, San Francisco
~3,000 participants
Updated 2026-07-15 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incident AF [At Risk Group]
Measured over 10 years
+1 more outcome measured

Conditions

Atrial Fibrillation

Explore related trials

Atrial FibrillationAtrial FlutterSupraventricular Tachycardia

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Jeffrey E Olgin, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
  • Edward P Gerstenfeld, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
  • Mark J Pletcher, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
  • Gregory Marcus, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \> 65 years of age
A diagnosis of hypertension
A diagnosis of diabetes
A diagnosis of sleep apnea
A BMI ≥ 30
Stable HF with preserved or reduced ejection fraction (NYHA Class I, II or III)
CKD not requiring dialysis 5. More than 5% PAC burden on ambulatory ECG monitoring (e.g. Holter, Ziopatch, Lifewatch, etc.) 6. Patients undergoing EP study or ablation for SVT with no history of AF and not meeting any of the above criteria (a-c).

What this trial measures

  • Incident AF [At Risk Group]10 years

    Incident AF is defined as the development of a new onset AF in subjects who do not have a previous AF diagnosis. This will be evaluated by detection of arrhythmias by use of ambulatory ECG monitoring (using an VivaLnk Wearable ECG patch and an AliveCor Kardia) and will be diagnosed by an automated algorithm that detects irregularly irregular rhythms. A random 50% of events will be overread by a cardiologist.

  • Progression of AF [AF Group]10 years

    Progression of AF is defined as increase in AF burden which is the amount of time spent in AF over the course of one month as determined by use of ambulatory ECG monitoring (using an VivaLnk Wearable ECG patch and an AliveCor Kardia) and will be diagnosed by an automated algorithm that detects irregularly irregular rhythms. A random 50% of events will be overread by a cardiologist.